	Application No.	Applicant(s)	
•	10/822,231	LAZAR ET AL.	
Notice of Allowability	Examiner	Art Unit	
	Chun Crowder	1644	,
The MAILING DATE of this communication app III claims being allowable, PROSECUTION ON THE MERITS IS erewith (or previously mailed), a Notice of Allowance (PTOL-85 IOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R If the Office or upon petition by the applicant. See 37 CFR 1.313	(OR REMAINS) CLOSED in or other appropriate commisting the commister of the commission of the c	n this application. If not included unication will be mailed in due course	e. THIS ne initiativ
. \boxtimes This communication is responsive to <u>06/20/2007, 07/05/20</u>	007 and 07/06/2007.		
. ⊠ The allowed claim(s) is/are <u>46</u> .			
Acknowledgment is made of a claim for foreign priority u a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority do International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" noted below. Failure to timely comply will result in ABANDONN THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.	e been received. e been received in Applicati cuments have been receive of this communication to file	on No ed in this national stage application fro	
A SUBSTITUTE OATH OR DECLARATION must be submined in the part of the property of the pro	es reason(s) why the oath o st be submitted. son's Patent Drawing Revie	or declaration is deficient.	E OF
 hereto or 2) to Paper No./Mail Date including changes required by the attached Examiner Paper No./Mail Date 		or in the Office action of	
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the same of			of
 DEPOSIT OF and/or INFORMATION about the depo- attached Examiner's comment regarding REQUIREMENT 			ne
Attachment(s) . ☐ Notice of References Cited (PTO-892) . ☐ Notice of Draftperson's Patent Drawing Review (PTO-948) . ☐ Information Disclosure Statements (PTO/SB/08), Paper No./Mail Date 06/26/2007 . ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	6. ⊠ Interview S Paper No 7. ⊠ Examiner's	nformal Patent Application Summary (PTO-413), /Mail Date s Amendment/Comment s Statement of Reasons for Allowance	e
	э. <u>—</u> Оттег	<u>-</u> ·	

Application/Control Number: 10/822,231

Art Unit: 1644

DETAILED ACTION

1. Applicant's amendment, filed on June 20, 2007, has been entered.

Claims 1-45 have been canceled.

Claim 46 has been added.

EXAMINER'S AMENDMENT

- 2. An Examiner's Amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the Issue Fee.
- 3. Authorization for this Examiner's Amendment was given in a telephone interview with applicant's representative Robin Silva on 07/05/2007.

In the Specification:

- 4. In the TITLE: "Optimized Fc variants and methods for their generation" has been replaced with -- Optimized Fc Variants --.
- 5. See attached Amendment to the Specification for a current copy of the paragraph [001] of the specification.
- 6. See attached Amendments to the Claims for a current copy of the claims including the current amendments to the claims.

Application/Control Number: 10/822,231 Page 3

Art Unit: 1644

REASONS FOR ALLOWANCE

7. The following is an Examiner's Statement for Reasons for Allowance:

In light of applicant's amendment to the claims, filed on June 20, 2007, and the filing of Terminal Disclaimers in compliance with 37 CFR 1.321(c) or 1.321(d) on January 17, 2007, the previous rejections under 35 U.S.C. 112, first paragraph enablement and written description and obvious double patenting over copending USSN 10/672,280 have been withdrawn. Further, applicant asserts that the instant application and USSN 10/672,280 were commonly owned at the time this invention was made (see Communication after Final filed on July 6, 2007).

Accordingly, the instant claims are deemed allowable.

- 8. Any comments considered necessary by applicant must be submitted no later than the payment of the Issue Fee and, to avoid processing delays, should preferably accompany the Issue Fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance".
- 9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Chun Crowder whose telephone number is (571) 272-8142. The examiner can normally be reached Monday through Friday from 8:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/822,231


Art Unit: 1644

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Chun Crowder, Ph.D.
Patent Examiner
July 5, 2007

PHILLIP GAMBEL, PH.D. TO PRIMARY EXAMINER TO 16 00


7/9/67



Listing of Claims

Claims 1-45 (Cancelled).

46. (New) An antibody and/or or an immunoadhesin of a parent Fc polypeptide, said antibody and/or or immunoadhesin comprising an amino acid modification at position 332 in the Fc region of said parent Fc polypeptide, wherein said antibody and/or or immunoadhesin protein exhibits altered binding to an FcγR as compared to said parent Fc polypeptide, wherein numbering is according to the EU index.



Amendment to the Specification

Please replace paragraph [001] on page 1, with the following rewritten paragraph:

--This Application is a continuation-in-part of U.S. Serial Number 10/672,280, filed September 26, 2003, which claims the benefit of the filing date under 35 U.S.C. § 119(e) to U.S.S.N.s 60/477,839 filed June 12, 2003; 60/467,606 filed May 2, 2003; 60/414,433 filed September 27, 2002; and 60/442,301 filed January 23, 2003, and is a continuation-in-part of U.S.S.N. 10/379,392, filed March 3, 2003, which is now abandoned, all of which are expressly incorporated by reference in their entirety. U.S.S.N. 10/379,392 claims the benefit of 35 U.S.C. § 119(e) to U.S.S.N.s 60/384,197, filed May 29, 2002 and 60/360,843, filed March 1, 2002.